Novo Nordisk Shares Plummet 15% Following Disappointing Weight Loss Drug Trial Results
Shares of Danish pharmaceutical giant Novo Nordisk experienced a sharp decline of 15% on Monday following the announcement that its experimental obesity treatment failed to demonstrate superiority over a competing medication from Eli Lilly in clinical trials.
The investigational drug, known as CagriSema, did not achieve its primary objective of proving non-inferiority in weight reduction compared to Eli Lilly’s tirzepatide after an 84-week study period, according to the company’s Monday morning announcement.
Tirzepatide serves as the active component in Eli Lilly’s highly successful medications Mounjaro and Zepbound, which have gained significant market share from Novo Nordisk’s semaglutide-based treatments Ozempic and Wegovy in terms of U.S. prescription volumes.
Trading on the Copenhagen exchange saw Novo Nordisk shares drop to 256 Danish kroner, marking the lowest valuation since June 2021, representing a 15% decline for the session.
Clinical trial participants who received a 2.4 mg dosage of CagriSema experienced a 23% reduction in body weight over the 84-week period, while those taking a 15 mg dose of tirzepatide achieved a superior 25.5% weight loss, the company reported.
The pharmaceutical company indicated plans to pursue additional clinical studies for CagriSema, potentially exploring higher dosage combinations. The treatment represents a significant investment for Novo Nordisk, as it combines semaglutide with cagrilintide, a pancreatic hormone that influences appetite regulation.
Chief Scientific Officer Martin Holst Lange expressed optimism about the drug’s potential, stating that CagriSema could become the first GLP-1/amylin combination therapy to reach market for obesity treatment. He emphasized that cagrilintide enhances semaglutide’s existing benefits and provides meaningful additional weight loss effects beyond what GLP-1 treatments alone can achieve. Lange noted that future studies would evaluate the complete weight-loss capabilities of CagriSema.
Despite these optimistic projections, Monday’s trial outcomes represent another setback for the Danish pharmaceutical company, particularly as it failed to outperform an already commercially available competitor. This disappointment follows a nearly 50% stock decline in 2025.
The company recently forecasted that sales and profit growth would decrease by 5% to 13% in 2026, citing increased competition, reduced pricing in the United States, and the expiration of patent protection for Wegovy and Ozempic in select markets.
Chief Executive Officer Mike Doustdar previously acknowledged the challenging period ahead, suggesting that investors should anticipate further declines before any recovery occurs.